<< Back to News

System Formulary Update
Eptinezumab-jjmr (Vyepti)

Situation

Vyepti (eptinezumab-jjmr) intravenous solution was approved for addition to the health system formulary at the November 2022 System Pharmacy and Therapeutics Committee meeting.

Background

The following medication was reviewed: eptinezumab-jjmr (Vyepti) 100 mg/mL intravenous solution 

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Medication Formulary with restriction to outpatient/clinic use only (ie, no inpatient use):

• Eptinezumab-jjmr (Vyepti) 100 mg/mL intravenous solution

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, December 13, 2022.